Hospitals and major drugmakers are battling over the financial impact of a government pilot program that could shake up how medicines are steeply discounted for low-income and uninsured patients. Over a thousand comments weighed in on the US Department of Health and Human Services’ proposed pilot program that would shift how pharmaceutical manufacturers provide discounted medicines to covered entities under the federal 340B Drug Pricing Program. “It needs to be one that can be useful to all manufacturers, not just a few,” said Heath Ingram, a partner at Goodwin’s Life Sciences group. “The concern manufacturers have is that if the 340B program continues to grow at an unchecked level, at a certain point, it’s going to negatively impact the drug manufacturers’ capacity to innovate,” Ingram said. “The model is an improved way of trying to track duplicate discounts or diversion in a complicated system where it’s hard to get access to quality data.” Read the Bloomberg Law article for more.